Stay updated on FG-4592 Study in ESRD Patients on Hemodialysis in China Clinical Trial

Sign up to get notified when there's something new on the FG-4592 Study in ESRD Patients on Hemodialysis in China Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the FG-4592 Study in ESRD Patients on Hemodialysis in China Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:49:47.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy and safety evaluation of FG-4592 in maintaining hemoglobin levels for subjects with End-Stage Renal Disease receiving maintenance hemodialysis and epoetin alfa.
    Difference
    0.1%
    Check dated 2024-06-06T14:50:24.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to provide detailed eligibility criteria for study participants, including specific health conditions and prior treatments required for inclusion. Previously, it only mentioned that no information was provided for investigators.
    Difference
    32%
    Check dated 2024-05-22T21:38:33.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T21:55:30.000Z thumbnail image

Stay in the know with updates to FG-4592 Study in ESRD Patients on Hemodialysis in China Clinical Trial

Enter your email address, and we'll notify you when there's something new on the FG-4592 Study in ESRD Patients on Hemodialysis in China Clinical Trial page.